Viralgen: Enabling seamless tech transfers

Enabling seamless tech transfers

How QbDVision helped CDMO Viralgen reduce total tech transfer time from 6-12 months to 3 months

With QbDVision, Viralgen onboards new customers in 75% less time

When a pioneering clinical-stage gene therapy company came to them with an innovative AAV product and a dramatically compressed timeline, Viralgen didn’t walk into the kickoff with spreadsheets and MSFT templates. They came with their new customer’s process pre-built in a run-ready digital platform that accelerated onboarding from Day 1. The result: Not only a handoff executed with unprecedented speed, efficiency, and precision, but also a transformational new approach to tech transfers that helped Viralgen set a new standard for CDMO partnerships.

What this top CDMO delivered with our platform

Minimized friction

Prebuilt process platform, structured templates, and dynamic visualizations that simplified and accelerated alignment.

Confident collaboration

Single source of truth where quality, risk, and process data are structured, visible, and immediately actionable for every stakeholder.

Customer trust

Speed, preparation, and ease of use that built a new partner’s confidence in Viralgen’s process, infrastructure, and professionalism.

Key QbDVision tools

• Structured QTPP & CQA templates
• Pre-configured process maps
• Digital risk assessment framework

From five-alarm workflows to a foundation of scalable excellence

Empowered by our QbDVision, Viralgen laid the groundwork for countless successful partnerships to come. Together, we built a model they can scale confidently, repeatably, and without compromise, strengthening each new collaboration with the structure that powered the first.

From the very first walkthrough, the client could see that we were ready to start work: We weren’t just presenting a plan, we were ready to execute it. QbDVision makes tech transfers feel less like a handoff and more like a hand-in-glove fit.

Isabel Guerrero, MSAT Senior Scientist, Viralgen

Before QbDVision

• 6–12 months to onboard a new gene-based product
• Handoffs via chaotic, redundant, disconnected documents
• Inconsistent clarity on responsibilities and review tasks
• Constant delays in stakeholder reviews and signoffs
• Unstructured risk assessments based on asynchronous data

With QbDVision

• 3-month accelerated onboarding process
• Centralized workspace with version control
• Clear, predefined review points with visual process tree
• Real-time, collaborative reviews and instant approvals
• Digitized, templated, collaborative risk analyses

Digital Standardization: Accelerating Gene Therapy Tech Transfer With Confidence and Compliance

By standardizing and consolidating platform knowledge in QbDVision, Viralgen transformed their tech transfer process. Having a shared digital workspace with their CDMO sponsor enabled real-time collaboration that cut timelines without sacrificing compliance.

In this white paper, you’ll learn:

• How Viralgen utilized QbDVision to align with their sponsor and complete core QbD deliverables faster
• Key enablers of a data-driven sponsor onboarding process
• How this approach creates a scalable model for future gene therapy manufacturing

‍

‍